English
IL15/IL15Ra Lentivirus
IL15/IL15Ra Lentivirus
Artikelnummer
BPS78938
Verpackungseinheit
500 µl x 2
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Applications: • Expression of human IL15/IL15Ra in cells of interest.• Arming CAR-T and CAR-NK cells with IL15/IL15Ra fusion protein.• Generate cell pools or stable cell lines expressing IL15/IL15Ra following puromycin selection
Background: IL15 (interleukin 15) and its high affinity receptor (IL15R) are involved in NK cell development and proliferation and persistence of CD8+ T cells, NKT cells, δγT cells and NK cells. The use of membrane bound IL15 as part of the CAR in T cells has been in use for a few years, as a way to improve T cell persistence in vivo. IL15 has a short half-life and requires treatment in high dosages, so research into ways to increase its potency has been ongoing. RLI-15 (receptor-linker-IL-15) is considered a super agonist composed of IL15 and an IL15Rα domain. This fusion protein was designed to bypass the need for endogenous IL15Rα to take advantage of IL15. It has been shown to activate proliferation and activity of NK. RLI-15 resulted in a potent effect in cell models. Recently the use of a CAR containing IL15/IL15Rα and targeting CD19 in NK92 cells has also resulted in increased proliferation, cytokine secretion and cytotoxicity towards B-cell cancer cell lines. The inclusion of IL15/IL15Rα fusion proteins to armor CARs represents a step forward in the fight against solid tumors.
Description: IL15/IL15Ra Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These particles result in expression of human IL15 (NM_000585.4) and IL15Rα (NM_002189.3) driven by an EF1a promoter, and a puromycin selection marker (Figure 1). IL15 and IL15Ra are fused via a glycine-serine linker.
Formulation: The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations and produced at higher titers by special request, for an additional fee.
Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
References: Hurton L., et al., 2016 Proc Natl Acad Sci USA 113 (48): E7788-E7797.
Fujii R., et al., 2018 Cancer Immunol Immunother. 67(4):675-689.
Desbois M., et al., 2020 Journal for ImmunoTherapy of Cancer 8:e000632.
Silvestre R., et al., 2023 Front. Immunol. 14: https://doi.org/10.3389/fimmu.2023.1226518.
Applications: • Expression of human IL15/IL15Ra in cells of interest.• Arming CAR-T and CAR-NK cells with IL15/IL15Ra fusion protein.• Generate cell pools or stable cell lines expressing IL15/IL15Ra following puromycin selection
Background: IL15 (interleukin 15) and its high affinity receptor (IL15R) are involved in NK cell development and proliferation and persistence of CD8+ T cells, NKT cells, δγT cells and NK cells. The use of membrane bound IL15 as part of the CAR in T cells has been in use for a few years, as a way to improve T cell persistence in vivo. IL15 has a short half-life and requires treatment in high dosages, so research into ways to increase its potency has been ongoing. RLI-15 (receptor-linker-IL-15) is considered a super agonist composed of IL15 and an IL15Rα domain. This fusion protein was designed to bypass the need for endogenous IL15Rα to take advantage of IL15. It has been shown to activate proliferation and activity of NK. RLI-15 resulted in a potent effect in cell models. Recently the use of a CAR containing IL15/IL15Rα and targeting CD19 in NK92 cells has also resulted in increased proliferation, cytokine secretion and cytotoxicity towards B-cell cancer cell lines. The inclusion of IL15/IL15Rα fusion proteins to armor CARs represents a step forward in the fight against solid tumors.
Description: IL15/IL15Ra Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These particles result in expression of human IL15 (NM_000585.4) and IL15Rα (NM_002189.3) driven by an EF1a promoter, and a puromycin selection marker (Figure 1). IL15 and IL15Ra are fused via a glycine-serine linker.
Formulation: The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations and produced at higher titers by special request, for an additional fee.
Storage Stability: Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
Supplied As: Two vials (500 µl x 2) of lentivirus at a titer ≥107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
References: Hurton L., et al., 2016 Proc Natl Acad Sci USA 113 (48): E7788-E7797.
Fujii R., et al., 2018 Cancer Immunol Immunother. 67(4):675-689.
Desbois M., et al., 2020 Journal for ImmunoTherapy of Cancer 8:e000632.
Silvestre R., et al., 2023 Front. Immunol. 14: https://doi.org/10.3389/fimmu.2023.1226518.
| Artikelnummer | BPS78938 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 78938 |
| Green Labware | Nein |
| Verpackungseinheit | 500 µl x 2 |
| Mengeneinheit | PAK |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
